Neoplasma最新文献

{"title":"Afatinib combined with oral metronomic vinorelbine as second-line treatment for advanced lung squamous cell carcinoma: a retrospective cohort study.","authors":"Chen Yin, Binfeng Li, Xi Lin, Aoli Zhang, Yi Peng, Jing Tang, Xiaobing Li","doi":"10.4149/neo_2026_260506N141","DOIUrl":"https://doi.org/10.4149/neo_2026_260506N141","url":null,"abstract":"<p><p>The aim of this study was to evaluate the efficacy and safety of afatinib combined with oral metronomic vinorelbine as a second-line treatment for patients with advanced lung squamous cell carcinoma (LSCC). A retrospective analysis was conducted on 38 patients with advanced LSCC who had failed first-line platinum-based doublet chemotherapy combined with immunotherapy between January 2022 and June 2024. All patients received afatinib (30 mg or 40 mg orally once daily) combined with oral metronomic vinorelbine (20 mg or 30 mg orally three times weekly on Monday, Wednesday, and Friday) until disease progression or unacceptable toxicity. The primary endpoints were objective response rate (ORR) and progression-free survival (PFS). Secondary endpoints included overall survival (OS), disease control rate (DCR), and treatment-related adverse events (TRAEs). Based on the data, the ORR was 26.3%, and the DCR was 68.4%. The median PFS was 5.0 months (95% CI: 4.7-5.4), and the median OS was 9.0 months (95% CI: 8.6-10.0). Grade ≥3 TRAEs occurred in 23.7% (9/38) of patients, including diarrhea (5.3%), rash (5.3%), neutropenia (5.3%), stomatitis (2.6%), and fatigue (2.6%). No grade 4-5 TRAEs or treatment-related deaths occurred. To conclude, the combination of afatinib and oral metronomic vinorelbine demonstrates promising antitumor activity and a manageable safety profile as a second-line treatment for advanced LSCC. This combo could represent an option as second-line after failure of chemo+IO.</p>","PeriodicalId":19266,"journal":{"name":"Neoplasma","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148796070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RNA-binding protein hnRNPD promotes the proliferation of Wilms' tumor cells through activating the p38 MAPK signaling pathway.","authors":"Chunlei Yang, Man Liao, Haibin Bao, Haolun Xu, Jun Wang, Man Zhang, Can Li, Tian Zheng, Gang Li","doi":"10.4149/neo_2026_251230N536","DOIUrl":"https://doi.org/10.4149/neo_2026_251230N536","url":null,"abstract":"<p><p>Wilms' tumor (WT) represents a kidney carcinoma predominantly affecting children aged five years and younger. Heterogeneous nuclear ribonucleoprotein D (hnRNPD), an RNA-binding protein, has been implicated in oncogenic processes across various tumor types, whereas its expression pattern and biological function in WT remain largely unknown. hnRNPD expression within WT tissues was evaluated using publicly available databases, and co-expressed genes were identified through bioinformatic analysis. In vitro, hnRNPD expression in WT cell lines 17.94 and HFWT was modulated via gene silencing or overexpression. We subsequently carried out functional assays to assess cell proliferation and apoptosis. Molecular experiments were conducted to determine p38 mitogen-activated protein kinase (p38 MAPK) pathway activation status within cells with altered hnRNPD expression. Furthermore, SB203580 was utilized to pharmacologically inhibit this pathway to investigate the mechanism of hnRNPD in regulating WT cell proliferation. Data showed that hnRNPD was upregulated in WT tissues and cells. Silencing hnRNPD significantly inhibited WT cell proliferation and promoted apoptosis. Conversely, overexpression of hnRNPD produced the opposing effects. MAPK14, the gene encoding the p38α isoform of p38 MAPK, was identified as a core gene within the hnRNPD co-expression network. Furthermore, the phosphorylation level of p38 MAPK in WT cells was markedly elevated compared to that in normal cells. However, inhibition of the p38 MAPK pathway using SB203580 suppressed WT cell proliferation. Notably, SB203580 effectively counteracted the pro-proliferative effect of hnRNPD overexpression on malignant WT cell growth. In conclusion, hnRNPD is highly expressed in WT and plays a significant role in promoting the malignant proliferation of WT cells. The underlying molecular mechanism involves the regulation of p38 MAPK signaling pathway activation.</p>","PeriodicalId":19266,"journal":{"name":"Neoplasma","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148707376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CRISPR/Cas9-edited organoids as a platform for tailored research of colorectal cancer.","authors":"Nikoleta Mojzesova, Petra Hladikova, Zuzana Kozovska, Martina Poturnajova, Silvia Tyciakova, Miroslava Matuskova","doi":"10.4149/neo_2026_260529N175","DOIUrl":"https://doi.org/10.4149/neo_2026_260529N175","url":null,"abstract":"<p><p>Colorectal cancer is one of the most commonly diagnosed cancers worldwide. Mortality rates and limited therapeutic options justify the development of reliable preclinical research models, as their translational value remains limited. Simple in vitro models do not recapitulate tumor heterogeneity, while in vivo research faces ethical concerns and interspecies differences. Patient-derived organoids offer a physiologically more relevant platform that retains the genetic, epigenetic, and phenotypic characteristics of the original tumor. Tumor-derived organoids enable precise investigation of novel treatments, functional genomics, and modeling of cancer development. Integration with CRISPR/Cas9 gene editing further enables accurate manipulation of specific genes to study carcinogenesis and therapeutic resistance. This review highlights recent advances in the use of organoids for colorectal cancer research and explores the potential of gene-edited organoids to discover the genetic and molecular mechanisms underlying colorectal cancer development, progression, and treatment resistance.</p>","PeriodicalId":19266,"journal":{"name":"Neoplasma","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148670193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuroimmune treatment of advanced solid tumors: 3-year survival after angiotensin 1-7, pineal indoles, and cannabinoids.","authors":"Paolo Lissoni, Alejandra Monzon, Savino Marroccoli, Giuseppe Di Fede, Andrea Sassola, Giusy Messina, Ana Cristina Simoes-E-Silva, Irina V Kuznetsova, Denis I Burchakov, Maria Yu Kirillova, Daniel Pedro Cardinali","doi":"10.4149/neo_2026_260610N190","DOIUrl":"https://doi.org/10.4149/neo_2026_260610N190","url":null,"abstract":"<p><p>In a recent study, the exogenous administration of angiotensin 1-7 (Ang 1,7) together with melatonin, 5-methoxytryptamine, and cannabidiol increased 1-year survival in advanced cancer patients, underlining the utility of neuromodulation in oncology. We now report a single-arm interventional study to evaluate the effectiveness of introducing Ang 1-7 in the neuroimmune regime, including pineal indoles and cannabinoids. Two cohorts of patients with advanced solid tumors refractory to standard oncologic treatments and with an estimated life expectancy of less than six months were studied. The full neuroimmune regimen cohort consisted of 100 consecutive patients treated over the last three years with Ang 1-7, pineal indoles, and cannabinoids, while the comparator cohort included 212 consecutive patients treated between 2015 and 2019 with pineal indoles and cannabinoids alone. Gastroprotected capsules of Ang 1-7 coupled with cyclodextrin were administered at 0.5 mg p.o. twice/day. Melatonin (100 mg) and 5-methoxytryptamine (20 mg) were given p.o. at bedtime and in the early afternoon, respectively. Cannabidiol or cannabigerol (in the case of glioblastoma) was given at 20 mg p.o. twice/day. Clinical response, disease control, and overall survival, along with the lymphocyte-to-monocyte ratio, were evaluated. In the full regimen cohort, disease control was achieved in 67 of 100 patients, with objective tumor regression observed in 23%. In the comparator cohort, disease control was obtained in 111 of 212 patients, with objective regression in 8%. Three-year overall survival was significantly higher in the full regimen cohort (37%) compared with the comparator cohort (19%). Both treatments were associated with a significant increase in the lymphocyte-to-monocyte ratio, suggesting an improvement in systemic immune status. The addition of Ang 1-7 to a neuroimmune regimen combining pineal indoles and cannabinoids was associated with improved disease control and long-term survival in patients with end-stage solid tumors lacking effective therapeutic options.</p>","PeriodicalId":19266,"journal":{"name":"Neoplasma","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148670196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"YTHDF2-regulated hsa_circ_0005882 functions as a sponge for miR-654-3p to suppress nasopharyngeal carcinoma proliferation.","authors":"Xu Wang, Aiyu Ma, Lu Lu, Qiuyu Zhao, Yuzhong Yang, Xuan Meng, Yiping Sun, Shuming Wang, Zhiyi Chen, Yan Zhang, Jinhua Zheng, Xiang Zheng","doi":"10.4149/neo_2026_260223N45","DOIUrl":"10.4149/neo_2026_260223N45","url":null,"abstract":"<p><p>Circular RNAs (circRNAs) are a subclass of non-coding RNAs, playing an important regulatory role in tumor progression. Accumulating evidence has revealed that circRNAs can be regulated by m6A machinery, influencing their expression and biological functions. However, the functions and mechanisms of m6A-mediated circRNAs in nasopharyngeal carcinoma (NPC) remain to be elucidated. In this study, the sequence of hsa_circ_0005882 (circ_0005882) was determined by Sanger sequencing, and its localization in both the cytoplasm and nucleus was confirmed by fluorescence in situ hybridization. Furthermore, m6A RNA immunoprecipitation followed by qPCR (MeRIP-qPCR) and the single-base elongation- and ligation-based qPCR amplification (SELECT) assays revealed that circ_0005882 may harbor m6A modifications. Overexpression of circ_0005882 significantly suppressed NPC cell proliferation. Mechanistically, the m6A reader YTHDF2 binds to circ_0005882 to promote its degradation, thereby reducing circ_0005882 stability. Additionally, circ_0005882 functions as a sponge for miR-654-3p, contributing to the inhibition of NPC proliferation. These findings collectively demonstrate that circ_0005882, which is negatively regulated by YTHDF2, functions as a tumor suppressor by sponging miR-654-3p to inhibit NPC cell proliferation, unveiling a novel regulatory model centered on the YTHDF2/circ_0005882/miR-654-3p axis in NPC pathogenesis.</p>","PeriodicalId":19266,"journal":{"name":"Neoplasma","volume":" ","pages":"269-282"},"PeriodicalIF":2.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148422982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevation of cardiac biomarkers after allogeneic transplantation: the impact of hematopoietic stem cell cryopreservation.","authors":"Vladimíra Lábska, Beáta Mladosievičová, Michaela Martišová, Barbora Žiaková, Eva Bojtárová, Ladislav Sopko, Jozef Lukáš, Ľubica Harvanová","doi":"10.4149/neo_2026_251203N506","DOIUrl":"10.4149/neo_2026_251203N506","url":null,"abstract":"<p><p>Hematopoietic stem cell transplantation (HSCT) represents a curative treatment modality for numerous hematologic malignancies. Advances in treatment protocols and supportive care have markedly enhanced post-transplant survival rates. Consequently, the number of long-term survivors has increased. However, HSCT may induce organ and tissue injury of varying severity, ranging from subclinical alterations to severe, potentially fatal complications. The aim of this study was to quantify plasma levels of the cardiac biomarkers: N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitive cardiac troponin T (hs-cTnT), and to evaluate cardiovascular (CV) complications in patients undergoing HSCT with and without cryopreservation of stem cells. During the COVID-19 pandemic, the use of cryopreserved allografts increased. Dimethyl sulfoxide (DMSO) is a cryoprotectant added to cell media to prevent ice formation and subsequent cell death during the freezing process of cryopreserved grafts. This study included 106 consecutive hematologic patients who underwent allogeneic HSCT. Serial measurements of plasma NT-proBNP and hs-cTnT concentrations were performed on the day before the conditioning regimen (baseline), on the day after HSCT (D+1), and subsequently on days D+2, D+7, D+14, and D+30, or at the onset of clinical symptoms. Newly diagnosed cardiac events post-HSCT were evaluated. NT-proBNP concentrations increased in all patients on D+1 after HSCT, reaching their peak at that time. Thereafter, NT-proBNP levels showed a gradual decline, but they did not return to baseline. A statistically significant increase in NT-proBNP values was observed in the group of patients who received cryopreserved grafts compared to those who received non-cryopreserved grafts. Hs-cTnT values during the early post-transplant period were comparable to pre-transplant levels in both groups - in patients who received cryopreserved grafts and also in patients who received non-cryopreserved grafts. After transplantation, we observed persistent hs-cTnT levels above the cut-off value in 28% of patients. Clinically significant CV complications were identified in 10 (9.4%) patients. Patients with manifest CV complications had significantly higher concentrations of both cardiomarkers compared with those without CV complications. In conclusion, persistent elevation in cardiac biomarkers may indicate a reduced functional myocardial reserve or diminished cardiac tolerance to cardiac stressors. Potential cardiac toxicity related to DMSO exposure in cryopreserved grafts should be considered in the differential diagnosis of cardiac events following HSCT involving cryopreserved stem cells.</p>","PeriodicalId":19266,"journal":{"name":"Neoplasma","volume":" ","pages":"310-317"},"PeriodicalIF":2.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148391476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world clinical outcomes of newly diagnosed AML unfit for intensive chemotherapy treated with venetoclax and azacitidine: does it depend on the number of days of venetoclax administration?","authors":"Jozef Lukáš, Balázs Gálffy, Stanislava Fliegová, Zuzana Sninská, Ľubica Harvanová, Katarína Slezáková, Ladislav Sopko","doi":"10.4149/neo_2026_260404N105","DOIUrl":"10.4149/neo_2026_260404N105","url":null,"abstract":"<p><p>Until 2020, patients with acute myeloid leukemia (AML) who were not suitable for intensive treatment were mostly limited to symptomatic and palliative care, or to low-intensity regimens including low-dose cytosine-arabinoside (ARA-C) and azacitidine (AZA) monotherapy, which didn't bring much benefit. The situation changed with the arrival of venetoclax, a Bcl-2 inhibitor that causes leukemic cells to rapidly undergo apoptosis. The aim of our retrospective study was to summarize the treatment outcomes of all newly diagnosed patients with AML, unsuitable for intensive chemotherapy, treated with a combination of venetoclax and AZA at the Department of Hematology and Transfusion Medicine, University Hospital in Bratislava from January 1, 2021, to December 31, 2025. A total of 108 patients underwent treatment with a median follow-up of 35.9 months; median age was 69.5 years (47-84 years), and median number of cycles was 3 (1-34). Induction mortality rate was 7.4%, and tumor lysis syndrome occurred in 4.5%. The overall response rate, which included the number of complete remissions, complete remissions with incomplete hematopoietic recovery, and morphologically leukemia-free status (CR/CRi/MLFS), was 64%, the median overall survival was 9 months, and disease-free survival was 8 months. As of December 31, 2025, 23 patients are alive, and 85 have died. The main cause of death was the progression of the disease. The main contribution of our study is the finding that shortening the duration of venetoclax treatment maintains efficacy. There was no significant difference in remission rate achieved or in overall survival based on the number of days of venetoclax administration (<14 vs. 14 vs. 21 vs. 28 days). The combination of AZA and venetoclax in AML has proven to be highly effective in inducing complete remission, usually immediately after the first cycle. Unfortunately, remission is not long-lasting, relapses are frequent, and the median overall survival in real-world data is 7.9 to 13.6 months.</p>","PeriodicalId":19266,"journal":{"name":"Neoplasma","volume":" ","pages":"295-300"},"PeriodicalIF":2.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148549945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A splice odyssey: periostin's journey through the sea of crabs.","authors":"Radka Macova, Michal Selc, Andrea Babelova","doi":"10.4149/neo_2026_260403N103","DOIUrl":"10.4149/neo_2026_260403N103","url":null,"abstract":"<p><p>Periostin is an extracellular matrix protein involved in processes ranging from early embryonic development to life-threatening cancer progression. Instead of acting as a single entity, it exists in numerous alternatively spliced isoforms, primarily differing in their C-terminal region, which drives diversification and context-dependence in its biological functions. Despite growing interest, inconsistencies in nomenclature and fragmented data still complicate the interpretation of isoform-specific roles. Therefore, the aim of this review is to provide a structured overview of periostin isoforms, focusing on their roles in development and carcinogenesis, while addressing challenges in their nomenclature. During embryogenesis, expression of periostin is dynamically regulated across developmental stages and tissues. Distinct isoforms exhibit specific patterns, both spatially and temporally, that reflect specialized functions during organogenesis (particularly in the cardiac, neural, and skeletal systems), and as experimental evidence points out, certain exons play critical roles in morphogenesis. Regulatory mechanisms influencing these patterns persist beyond development and are often changed in pathological conditions. In oncological diseases, expression of periostin isoforms varies widely between tumor types and microenvironments. Many isoforms are present in malignant as well as in adjacent non-malignant tissues, with differences in their relative abundance. Functionally, exon 17-containing variants tend to influence tumor cell-intrinsic properties, while variants with exon 21 are more closely linked to stromal interactions and modulation of the tumor microenvironment. Interesting is also the fact that periostin can exert both tumor-promoting and tumor-limiting effects, depending on the isoform and biological context. Taken together, periostin isoforms represent a complex regulatory system whose better understanding and standardized classification may enhance their potential in diagnostics and therapy.</p>","PeriodicalId":19266,"journal":{"name":"Neoplasma","volume":" ","pages":"251-260"},"PeriodicalIF":2.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148605733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The interplay between cancer and follicular fluid: molecular changes and tumor-promoting properties.","authors":"Dominika Melegová, Monika Šramková, Katarina Kozics","doi":"10.4149/neo_2026_260415N118","DOIUrl":"10.4149/neo_2026_260415N118","url":null,"abstract":"<p><p>Follicular fluid is a complex biological microenvironment essential for oocyte maturation and folliculogenesis. Alterations in follicular fluid composition have been associated with reproductive disorders reflecting compromised oocyte quality. Emerging evidence suggests that malignancies also significantly alter the composition of follicular fluid, potentially compromising the follicular microenvironment and impacting fertility preservation outcomes. Interestingly, the follicular fluid itself exhibits tumor-initiating and tumor-promoting properties, inducing DNA damage, pro-inflammatory signaling, mild proliferation, and suppressing apoptosis. Understanding cancer-associated follicular fluid alterations may improve fertility care, identify early biomarkers, and inform strategies for ovarian cancer prevention and therapy. This review aims to summarize current knowledge on how cancer can alter follicular fluid composition and its role in ovarian malignancies.</p>","PeriodicalId":19266,"journal":{"name":"Neoplasma","volume":" ","pages":"261-268"},"PeriodicalIF":2.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148265691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postoperative clinical prognosis in 160 cases of glioblastoma and efficacy of vascular targeted therapy for recurrence.","authors":"Jiayuan Li, Liubing Hou, Huandi Zhou, Zizhou Zhang, Yu Wang, Xiang Zhan, Wenyan Wang, Lei Tian, Xiaoying Xue","doi":"10.4149/neo_2026_260306N56","DOIUrl":"10.4149/neo_2026_260306N56","url":null,"abstract":"<p><p>Glioblastoma (GBM) is the most common primary malignant brain tumor. Concurrent chemoradiotherapy and adjuvant chemotherapy have become the standard treatment modalities after surgery. However, despite such aggressive treatment, the overall survival (OS) rate remains low, and the disease is highly prone to recurrence with an extremely poor prognosis after recurrence. Currently, there is no standard salvage treatment regimen. This study conducted a clinical prognostic analysis of 160 patients with GBM after surgery and evaluated the clinical efficacy of anti-angiogenic drugs (apatinib/bevacizumab) as salvage treatment after recurrence, providing a strong direction for future treatment. Among the 160 patients with GBM included in the study, univariate analysis showed that age, use of apatinib, adjuvant chemotherapy, and radiotherapy were significantly associated with OS, while gender, CD34 expression, Ki-67 expression, bevacizumab, and P53 expression were not significantly associated with OS. Multivariate analysis revealed that adjuvant chemotherapy, age, and radiotherapy were independent prognostic factors for OS in patients with GBM. The median OS of the entire cohort was 20.0 months, with 1-year, 3-year, and 5-year survival rates of 74.6%, 28.7%, and 12.4%, respectively. Analysis of the clinical efficacy of salvage chemotherapy in 65 patients with recurrent GBM showed that the combined anti-angiogenic drug group had a significant survival advantage compared to the chemotherapy-only group (33 months vs. 19 months). Among patients in the combined anti-angiogenic drug group, 36 patients achieved clinical control, with a disease control rate (DCR) of 73.47%, significantly higher than the 43.75% DCR in the control group. The chemotherapy combined with apatinib group had a significant survival advantage in OS (p=0.012) and also benefited in DCR (66.67% vs. 43.75%); however, the chemotherapy combined with the bevacizumab group did not show a survival benefit in OS (p=0.078).</p>","PeriodicalId":19266,"journal":{"name":"Neoplasma","volume":" ","pages":"301-309"},"PeriodicalIF":2.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148422970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}